Sir,
Phosphatase, homologue to tensin (PTEN), is a tumour suppressor protein that regulates the PI3K/AKT signalling pathway. Loss of PTEN expression results in overactivation of the Akt pathway and confers resistance to inhibitors of the epidermal growth factor receptor (EGFR). Recently, four clinical studies have evaluated the association between PTEN expression status and response to the treatment of EGFR-targeted monoclonal antibodies (cetuximab and panitumumab) in patients with metastatic colorectal cancer (mCRC) (Frattini et al, 2007; Loupakis et al, 2009; Molinari et al, 2009; Sartore-Bianchi et al, 2009). However, results are still inconclusive partially because of the relatively small sample size, and the retrospective and not controlled nature of these studies.
To derive a more precise estimation of the relationship, we performed this meta-analysis. The sample sizes in the four studies ranged from 12 to 85. In total, PTEN immunohistochemical analysis was performed successfully on 231 primary tumours. Loss of PTEN expression was detected in 87 (38%) primary tumours. Among 231 patients analysed, 205 patients were assessable for tumour response. The objective response rate (ORR) of mCRC patients with loss of PTEN expression was 6% (5 of 81), whereas the ORR of mCRC patients with normal PTEN expression was 32% (40 of 124). Loss of PTEN expression had a negative effect on tumour response to anti-EGFR monoclonal antibodies (pooled risk ratio, 0.22; 95% confidence interval, 0.10–0.50; P<0.001), with no heterogeneity between studies (P=0.22) (Table 1). No publication bias was found by Egger's test (t=1.44; P=0.45).
In conclusion, this meta-analysis suggests that loss of PTEN expression is associated with clinical resistance to EGFR-targeted monoclonal antibodies in patients with mCRC. However, the number of studies and the number of subjects included in the meta-analysis are relatively small. Large prospective studies using standardised unbiased methods are needed to confirm our results.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139–1145
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622–2629
Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L, Frattini M (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087–1094
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851–1857
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mao, C., Liao, RY. & Chen, Q. Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer. Br J Cancer 102, 940 (2010). https://doi.org/10.1038/sj.bjc.6605575
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605575
This article is cited by
-
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
Investigational New Drugs (2020)
-
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Chinese Journal of Cancer (2015)
-
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Drugs (2015)
-
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy
Cancer and Metastasis Reviews (2014)
-
Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies
Cancer Chemotherapy and Pharmacology (2012)